​

Lyell Immunopharma (LYEL) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Lyell Immunopharma Revenue Highlights

0

Latest Revenue (Q)

$8.00K

Main Segment (Y)

Reportable segment

Lyell Immunopharma Revenue by Period

Lyell Immunopharma Revenue by Year

DateRevenueChange
2024-12-31--100.00%
2023-12-31$130.00K-99.85%
2022-12-31$84.68M695.15%
2021-12-31$10.65M37.31%
2020-12-31$7.76M1080.52%
2019-12-31$657.00K-

Lyell Immunopharma generated - in revenue during NA 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Lyell Immunopharma Revenue by Quarter

DateRevenueChange
2025-06-30$8.00K14.29%
2025-03-31$7.00K-36.36%
2024-12-31$11.00K-67.65%
2024-09-30$34.00K161.54%
2024-06-30$13.00K333.33%
2024-03-31$3.00K-76.92%
2023-12-31$13.00K-48.00%
2023-09-30$25.00K-7.41%
2023-06-30$27.00K-58.46%
2023-03-31$65.00K34.34%
2022-12-31$48.39K1512.87%
2022-09-30$3.00K-99.99%
2022-06-30$35.74M6363.11%
2022-03-31$553.00K-80.40%
2021-12-31$2.82M2.43%
2021-09-30$2.75M4.83%
2021-06-30$2.63M7.48%
2021-03-31$2.44M5.75%
2020-12-31$2.31M116.07%
2020-09-30$1.07M-65.68%
2020-06-30$3.12M148.25%
2020-03-31$1.26M-

Lyell Immunopharma generated $8.00K in revenue during Q2 2025, up 14.29% compared to the previous quarter, and up 266.67% compared to the same period a year ago.

Lyell Immunopharma Revenue Breakdown

Lyell Immunopharma Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24
Reportable segment$61.00K

Lyell Immunopharma's latest annual revenue breakdown by segment (product or service), as of Dec 24: Reportable segment (100.00%).

Quarterly Revenue by Product

Product/ServiceJun 25Mar 25
Reportable segment$8.00K$7.00K

Lyell Immunopharma's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: Reportable segment (100.00%).

Lyell Immunopharma Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
BLRXBioLineRx$4.80M$6.86M
IMMPImmutep$3.51M$2.11M
ALLOAllogene Therapeutics$22.00K-
EDITEditas Medicine--
CADLCandel Therapeutics--
AARDAardvark Therapeutics--
KYTXKyverna Therapeutics--
REPLReplimune Group--
NMRANeumora Therapeutics--
TNYATenaya Therapeutics--
LYELLyell Immunopharma-$8.00K

LYEL Revenue FAQ

What is Lyell Immunopharma’s yearly revenue?

Lyell Immunopharma's yearly revenue for 2024 was $0, representing a decrease of -100.00% compared to 2023. The company's yearly revenue for 2023 was $130K, representing a decrease of -99.85% compared to 2022. LYEL's yearly revenue for 2022 was $84.68M, representing an increase of 695.15% compared to 2021.

What is Lyell Immunopharma’s quarterly revenue?

Lyell Immunopharma's quarterly revenue for Q2 2025 was $8K, a 14.29% increase from the previous quarter (Q1 2025), and a -38.46% decrease year-over-year (Q2 2024). The company's quarterly revenue for Q1 2025 was $7K, a -36.36% decrease from the previous quarter (Q4 2024), and a 133.33% increase year-over-year (Q1 2024). LYEL's quarterly revenue for Q4 2024 was $11K, a -67.65% decrease from the previous quarter (Q3 2024), and a -15.38% decrease year-over-year (Q4 2023).

What is Lyell Immunopharma’s revenue growth rate?

Lyell Immunopharma's revenue growth rate for the last 3 years (2022-2024) was -100.00%, and for the last 5 years (2020-2024) was -100.00%.

What are Lyell Immunopharma’s revenue streams?

Lyell Immunopharma's revenue streams in c 24 are Reportable segment

What is Lyell Immunopharma’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Lyell Immunopharma was Reportable segment. This segment made a revenue of $61K, representing 100.00% of the company's total revenue.